General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

N/ARecruitingNCT06807190

Novo Nordisk A/S630 enrolled

Overview

The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.

Study Type

OBSERVATIONAL

Enrollment

630

Conditions

Diabetes Mellitus, Type 1

Interventions

Insulin IcodecDRUG

Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available Awiqli has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Male or female with no age limitation. * Diagnosis of diabetes mellitus. There is no limitation for type of diabetes mellitus and prior treatment for diabetes mellitus. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Treatment with any investigational drug within 30 days prior to enrolment into the study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Contraindication described in Japanese package insert. * Participants showing hypoglycaemic symptoms. * Participants with a history of hypersensitivity to any ingredients of this drug.

Locations (106)

Outcomes

Primary Outcomes

Number of Adverse Reactions (ARs)

Measured as number of events.

Time frame: From baseline (week 0) to end of study (week 52)

Secondary Outcomes

Number of Adverse Events (AEs)

Measured as number of events.

Time frame: From baseline (week 0) to end of study (week 52)

Number of Serious Adverse Events (SAEs)

Measured as number of events.

Time frame: From baseline (week 0) to end of study (week 52)

Number of Serious Adverse Reactions (SARs)

Measured as number of events.

Time frame: From baseline (week 0) to end of study (week 52)

Change in Glycosylated Haemoglobin (HbA1c)

Measured as percentage (%) point of HbA1c.

Time frame: From baseline (week 0) to end of study (week 52)

Change in Fasting Plasma Glucose (FPG)

Measured as milligrams per decilitre (mg/dL).

Time frame: From baseline (week 0) to end of study (week 52)

Change in Diabetes Therapy-Related Quality Of Life (DTR-QOL)

DTR-QOL is a Japanese questionnaire assessing the influence of diabetes treatment on the individual health related quality of life on 4 domains: "burden on social activities and daily activities", "anxiety and dissatisfaction with treatment", "hypoglycaemia" and "satisfaction with treatment". DTR-QOL contains 29 questions and the response scale is a 7-point scale (1: strongly agree to 7: strongly disagree). The score of each item will be reversed so that "7: strongly disagree" represents the highest/desirable QOL. The total score, after simple addition of the item scores, is converted to 0 to 100 (best-case response is 100; worst case response is 0).

Central Contacts

Novo Nordisk

CONTACT

(+1) 866-867-7178 clinicaltrials@novonordisk.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT06807190 - General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus | Crick | Crick